Interestingly, targeting squalene epoxidase with an approved antifungal drug, terbinafine, suppressed NAFLD-induced HCC growth in vivo and in vitro, highlighting the therapeutic potential of terbinafine in the context of NAFLD-induced HCC. This evidence concerns the gene SQLE and metabolic dysfunction-associated steatotic liver disease.